文献速递遗传性与小管间质肾病

一种新型直接腺苷单磷酸激活蛋白激酶激活剂可改善常染色体显性多囊肾病临床前模型的疾病进展

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · Kidney Int · 2023-02-18

该研究在犬源和患者来源的3D囊肿模型及Pkd1敲除小鼠模型中评估了直接变构AMPK激活剂PXL770对常染色体显性多囊肾病的作用。PXL770激活AMPK并剂量依赖性减少囊肿生长,在Pkd1敲除小鼠中降低血尿素47%、囊肿指数26%、肾重体重比35%,并减少细胞增殖、巨噬细胞浸润和纤维化标志物。

要点

  • PXL770在犬源和患者来源的3D囊肿模型中剂量依赖性减少囊肿生长。
  • Pkd1敲除小鼠中PXL770降低血尿素47%、囊肿指数26%、肾重体重比35%。
  • PXL770降低细胞增殖标志物48%、巨噬细胞浸润53%、组织纤维化37%。

核心结论

  • 结果表明直接变构AMPK激活在治疗常染色体显性多囊肾病方面具有潜力,并支持PXL770用于该适应症的进一步开发。

研究设计与样本

  • 研究在犬源和患者来源的3D囊肿模型以及Pkd1敲除小鼠模型(可诱导的肾上皮特异性Pkd1敲除小鼠模型)中评估了PXL770的效果。

主要发现

  • PXL770在forskolin刺激的犬源Madin-Darby犬肾细胞和desmopressin刺激的患者来源肾上皮细胞中诱导AMPK激活并剂量依赖性减少囊肿生长。
  • 在Pkd1敲除小鼠中,PXL770与未治疗对照Pkd1敲除小鼠相比,降低血尿素47%、囊肿指数26%、肾重体重比35%。
  • PXL770降低细胞增殖标志物48%、巨噬细胞浸润53%、组织纤维化37%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) mainly results from mutations in the PKD1 gene, which encodes polycystin 1. It is the most common inherited kidney disease and is characterized by a progressive bilateral increase in cyst number and size, often leading to kidney failure. The cellular energy sensor and regulator adenosine monophosphate stimulated protein kinase (AMPK) has been implicated as a promising new therapeutic target. To address this hypothesis, we determined the effects of a potent and selective clinical stage direct allosteric AMPK activator, PXL770, in canine and patient-derived 3D cyst models and an orthologous mouse model of ADPKD. PXL770 induced AMPK activation and dose-dependently reduced cyst growth in principal-like Madin-Darby Canine Kidney cells stimulated with forskolin and kidney epithelial cells derived from patients with ADPKD stimulated with desmopressin. In an inducible, kidney epithelium-specific Pkd1 knockout mouse model, PXL770 produced kidney AMPK pathway engagement, prevented the onset of kidney failure (reducing blood urea by 47%), decreased cystic index by 26% and lowered the kidney weight to body weight ratio by 35% compared to untreated control Pkd1 knockout mice. These effects were accompanied by a reduction of markers of cell proliferation (-48%), macrophage infiltration (-53%) and tissue fibrosis (-37%). Thus, our results show the potential of direct allosteric AMPK activation in the treatment of ADPKD and support the further development of PXL770 for this indication.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Dagorn PG, Buchholz B, Kraus A, et al. A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2023. PMID: 36804411. doi:10.1016/j.kint.2023.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。